전신 영상 시장 규모, 점유율, 동향 분석 보고서 : 모달리티별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Whole Body Imaging Market Size, Share & Trends Analysis Report By Modality (CT, MRI, Nuclear Imaging), By Application (Oncology, Trauma And Emergency Care, Metastasis Detection), By End-use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,401,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,813,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,637,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

전신 영상 시장 규모와 동향:

전 세계 전신 영상 시장 규모는 2024년 295억 8,000만 달러로 2025년부터 2030년까지 연평균 5.94%로 성장할 것으로 예상됩니다.

산업 성장을 촉진하는 주요 요인으로는 진단의 정확성과 효율성을 높이는 급속한 기술 발전을 들 수 있습니다. 예방 검진에 대한 인식이 높아지면서 질병의 조기 발견 및 모니터링에 대한 수요가 증가하고 있습니다. 또한, 암, 심혈관질환과 같은 만성질환의 유병률이 증가함에 따라 첨단 영상 진단 솔루션이 요구되고 있습니다. 고령화로 인해 다양한 건강 상태에 노출되기 쉬운 고령화도 적시에 진단 및 치료 계획을 세우기 위해 전신 영상 기술의 채택이 증가하는 요인으로 작용하고 있습니다.

전신 영상 시스템은 한 번의 촬영으로 전신을 포괄적으로 볼 수 있기 때문에 국소적인 영상 기술보다 효율적입니다. 따라서 특정 부위를 대상으로 한 여러 번의 스캔이 필요하지 않아 환자가 반복적인 시술에 노출되는 것을 줄이고, 진단 지연을 최소화할 수 있습니다. 이러한 시스템은 여러 장기에 걸친 전이를 평가해야 하는 암과 같은 전신 질환을 식별하는 데 특히 효과적입니다. 또한 숨겨진 병변이나 혈관 상태, 여러 장기에 영향을 미치는 염증성 질환과 같이 국소 검사에서 간과될 수 있는 이상 징후를 발견하는 데도 도움이 됩니다.

CT와 MRI의 기술 발전은 촬영 정확도 향상, 스캔 시간 단축, 환자 편의성 향상을 가져와 시장 성장에 더욱 기여하고 있습니다. 고해상도 영상, AI를 활용한 진단 도구, 첨단 3D 영상 처리 기능 등의 혁신으로 복잡한 병태생리를 조기에 정확하게 발견할 수 있게 되었습니다. 또한, CT는 방사선량 감소, MRI는 조영효과 향상으로 보다 안전하고 효과적인 진단이 가능해져 다양한 의료 용도로의 채택이 더욱 확대되고 있습니다.

암, 심혈관질환, 당뇨병, 신경 질환 등 만성질환의 유병률 증가도 전신 영상 산업의 성장에 기여하는 주요 요인입니다. 이러한 질환들은 효과적인 관리를 위해 지속적인 모니터링과 조기 발견이 필요한 경우가 많기 때문에 CT나 MRI와 같은 첨단 영상 기술에 대한 수요가 증가하고 있습니다. 전신 영상은 만성질환의 진단, 병기 결정 및 진행 추적에 중요한 역할을 하며, 적시에 개입하고 환자의 예후를 개선할 수 있기 때문에 시장 확대에 박차를 가하고 있습니다.

목차

제1장 분석 방법·범위

제2장 주요 요약

제3장 전신 영상 시장 : 변수, 동향, 범위

• 시장 연관 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 전신 영상 시장 : 분석 툴
  • 업계 분석 : Porter's Five Forces 분석
  • PESTEL 분석

제4장 전신 영상 시장 : 모달리티별 추정·동향 분석

• 부문 대시보드
• 전신 영상 시장 변동 분석
• 전신 영상 시장 : 시장 규모 예측과 동향 분석, 모달리티별(2018-2030년)
• 컴퓨터 단층촬영(CT)
• 자기공명영상(MRI)
• 핵영상
• 기타 모달리티

제5장 전신 영상 시장 : 용도별 추정·동향 분석

• 부문 대시보드
• 전신 영상 시장 변동 분석
• 전신 영상 시장 : 시장 규모 예측과 동향 분석, 용도별(2018-2030년)
• 종양학
• 외상 및 응급의료
• 전이 검출
• 전신 건강 진단

제6장 전신 영상 시장 : 최종 용도별 추정·동향 분석

• 부문 대시보드
• 전신 영상 시장 변동 분석
• 전신 영상 시장 : 시장 규모 예측과 동향 분석, 최종 용도별(2018-2030년)
• 병원
• 영상 진단 센터
• 기타 최종사용자

제7장 전신 영상 시장 : 지역별 추정과 동향 분석(기술별·용도별·최종 용도별)

• 시장 점유율 : 지역별(2024년·2030년)
• 시장 대시보드 : 지역별
• 세계 시장 현황 : 지역별
• 시장 규모 예측과 동향 분석(2018-2030년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제8장 경쟁 구도

• 최신 동향과 영향 분석 : 주요 시장 진출 기업별
• 기업/경쟁 분류
• 주요 기업의 시장 점유율 분석(2024년)
• 기업 포지션 분석
• 기업 분류(신흥 기업, 이노베이터, 리더)
• 기업 개요
  • GE HealthCare
  • Koninklijke Philips NV
  • Siemens Healthineers AG
  • Canon Medical Systems
  • Fujifilm Holdings Corporation
  • Mediso Ltd.
  • NeuroLogica(a subsidiary of Samsung Electronics)
  • United Imaging Healthcare
  • Shimadzu Corporation

ksm

영문 목차

영문목차

Whole Body Imaging Market Size & Trends:

The global whole body imaging market size was valued at USD 29.58 billion in 2024 and is expected to grow at a CAGR of 5.94% from 2025 to 2030. Major factors driving the growth of the industry include rapid technological advancements that enhance diagnostic accuracy and efficiency. Rising awareness of preventive health checkups is fueling demand for early detection and monitoring of diseases. Additionally, the growing prevalence of chronic disorders such as cancer and cardiovascular diseases necessitates advanced imaging solutions. The aging population, being more prone to various health conditions, further contributes to the increased adoption of whole-body imaging technologies for timely diagnosis and treatment planning.

Whole-body imaging systems are more efficient than localized imaging techniques as they offer a comprehensive view of the entire body in a single session. This eliminates the need for multiple scans targeting specific regions, reducing patient exposure to repeated procedures and minimizing diagnostic delays. These systems are particularly effective in identifying systemic diseases such as cancer, where metastatic spread across multiple organs must be assessed. They also aid in detecting abnormalities that might be overlooked in regional scans, such as hidden lesions, vascular conditions, or inflammatory diseases affecting multiple systems.

Technological advancements in CT and MRI are further contributing to market growth as they enhance imaging precision, reduce scan times, and improve patient comfort. Innovations such as high-resolution imaging, AI-powered diagnostic tools, and advanced 3D imaging capabilities enable early and accurate detection of complex conditions. Additionally, reduced radiation doses in CT and improved contrast imaging in MRI ensure safer and more effective diagnostic procedures, further driving their adoption across diverse medical applications.

The increasing prevalence of chronic disorders, such as cancer, cardiovascular diseases, diabetes, and neurological conditions, is also a key factor contributing to the growth of the whole-body imaging industry. As these diseases often require ongoing monitoring and early detection for effective management, the demand for advanced imaging technologies like CT and MRI rises. Whole-body imaging plays a crucial role in diagnosing, staging, and tracking the progression of chronic disorders, allowing for timely interventions and improved patient outcomes, thereby fueling market expansion.

Global Whole Body Imaging Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global whole body imaging market report on the basis of modality, application, end-use, and region:

• Modality Outlook (Revenue, USD Million, 2018 - 2030)
• Computed Tomography (CT)
• Magnetic Resonance Imaging (MRI)
• Nuclear Imaging
• Other Modalities
• Application Outlook (Revenue, USD Million, 2018 - 2030)
• Oncology
• Trauma & Emergency Care
• Metastasis Detection
• Full-Body Health Screenings
• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals
• Diagnostic Imaging Centers
• Other End Users
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Modality
  • 1.2.2. Application
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Modality outlook
  • 2.2.2. Application outlook
  • 2.2.3. End use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Whole Body Imaging Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising prevalence of chronic diseases requiring comprehensive diagnostic imaging
    • 3.2.1.2. Advancements in imaging technologies
    • 3.2.1.3. Growing demand for early and accurate disease diagnosis
    • 3.2.1.4. Expanding applications of whole-body imaging in oncology, cardiology, and neurology
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of advanced whole-body imaging systems
    • 3.2.2.2. Limited reimbursement and insurance coverage
    • 3.2.2.3. Limited availability of skilled healthcare professionals
• 3.3. Whole Body Imaging Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Whole Body Imaging Market: Modality Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Whole Body Imaging Modality Market Movement Analysis
• 4.3. Global Whole Body Imaging Market Size & Trend Analysis, by Modality, 2018 to 2030 (USD Million)
• 4.4. Computed Tomography (CT)
  • 4.4.1. Computed tomography (CT) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Magnetic Resonance Imaging (MRI)
  • 4.5.1. Magnetic resonance imaging (MRI) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Nuclear Imaging
  • 4.6.1. Nuclear imaging market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Other Modalities
  • 4.7.1. Other modalities market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Whole Body Imaging Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Whole Body Imaging Application Market Movement Analysis
• 5.3. Global Whole Body Imaging Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Oncology
  • 5.4.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Trauma and Emergency Care
  • 5.5.1. Trauma and emergency care market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Metastasis Detection
  • 5.6.1. Metastasis detection market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Full-Body Health Screenings
  • 5.7.1. Full-body health screenings market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Whole Body Imaging Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Whole Body Imaging End Use Market Movement Analysis
• 6.3. Global Whole Body Imaging Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Diagnostic Imaging Centers
  • 6.5.1. Diagnostic imaging centers market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Other End Users
  • 6.6.1. Other End Users market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Whole Body Imaging Market: Regional Estimates & Trend Analysis By Technology, Application, End Use

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Competitive scenario
    • 7.5.1.3. Regulatory framework
    • 7.5.1.4. Reimbursement structure
    • 7.5.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Reimbursement structure
    • 7.5.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. Reimbursement structure
    • 7.5.3.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Competitive scenario
    • 7.6.1.3. Regulatory framework
    • 7.6.1.4. Reimbursement structure
    • 7.6.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Reimbursement structure
    • 7.6.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Reimbursement structure
    • 7.6.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Competitive scenario
    • 7.6.4.3. Regulatory framework
    • 7.6.4.4. Reimbursement structure
    • 7.6.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Competitive scenario
    • 7.6.5.3. Regulatory framework
    • 7.6.5.4. Reimbursement structure
    • 7.6.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Competitive scenario
    • 7.6.6.3. Regulatory framework
    • 7.6.6.4. Reimbursement structure
    • 7.6.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Competitive scenario
    • 7.6.7.3. Regulatory framework
    • 7.6.7.4. Reimbursement structure
    • 7.6.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Competitive scenario
    • 7.6.8.3. Regulatory framework
    • 7.6.8.4. Reimbursement structure
    • 7.6.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Competitive scenario
    • 7.7.1.3. Regulatory framework
    • 7.7.1.4. Reimbursement structure
    • 7.7.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Reimbursement structure
    • 7.7.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Reimbursement structure
    • 7.7.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Competitive scenario
    • 7.7.4.3. Regulatory framework
    • 7.7.4.4. Reimbursement structure
    • 7.7.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Competitive scenario
    • 7.7.5.3. Regulatory framework
    • 7.7.5.4. Reimbursement structure
    • 7.7.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Competitive scenario
    • 7.7.6.3. Regulatory framework
    • 7.7.6.4. Reimbursement structure
    • 7.7.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Competitive scenario
    • 7.8.1.3. Regulatory framework
    • 7.8.1.4. Reimbursement structure
    • 7.8.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.2. Argentina
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Competitive scenario
    • 7.8.2.3. Regulatory framework
    • 7.8.2.4. Reimbursement structure
    • 7.8.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Competitive scenario
    • 7.9.1.3. Regulatory framework
    • 7.9.1.4. Reimbursement structure
    • 7.9.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Competitive scenario
    • 7.9.2.3. Regulatory framework
    • 7.9.2.4. Reimbursement structure
    • 7.9.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Competitive scenario
    • 7.9.3.3. Regulatory framework
    • 7.9.3.4. Reimbursement structure
    • 7.9.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Competitive scenario
    • 7.9.4.3. Regulatory framework
    • 7.9.4.4. Reimbursement structure
    • 7.9.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Key company market share analysis, 2024
• 8.4. Company Position Analysis
• 8.5. Company Categorization (Emerging Players, Innovators and Leaders
• 8.6. Company Profiles
  • 8.6.1. GE HealthCare
    • 8.6.1.1. Company overview
    • 8.6.1.2. Financial performance
    • 8.6.1.3. Product benchmarking
    • 8.6.1.4. Strategic initiatives
  • 8.6.2. Koninklijke Philips N.V.
    • 8.6.2.1. Company overview
    • 8.6.2.2. Financial performance
    • 8.6.2.3. Product benchmarking
    • 8.6.2.4. Strategic initiatives
  • 8.6.3. Siemens Healthineers AG
    • 8.6.3.1. Company overview
    • 8.6.3.2. Financial performance
    • 8.6.3.3. Product benchmarking
    • 8.6.3.4. Strategic initiatives
  • 8.6.4. Canon Medical Systems
    • 8.6.4.1. Company overview
    • 8.6.4.2. Financial performance
    • 8.6.4.3. Product benchmarking
    • 8.6.4.4. Strategic initiatives
  • 8.6.5. Fujifilm Holdings Corporation
    • 8.6.5.1. Company overview
    • 8.6.5.2. Financial performance
    • 8.6.5.3. Product benchmarking
    • 8.6.5.4. Strategic initiatives
  • 8.6.6. Mediso Ltd.
    • 8.6.6.1. Company overview
    • 8.6.6.2. Financial performance
    • 8.6.6.3. Product benchmarking
    • 8.6.6.4. Strategic initiatives
  • 8.6.7. NeuroLogica (a subsidiary of Samsung Electronics)
    • 8.6.7.1. Company overview
    • 8.6.7.2. Financial performance
    • 8.6.7.3. Product benchmarking
    • 8.6.7.4. Strategic initiatives
  • 8.6.8. United Imaging Healthcare
    • 8.6.8.1. Company overview
    • 8.6.8.2. Financial performance
    • 8.6.8.3. Product benchmarking
    • 8.6.8.4. Strategic initiatives
  • 8.6.9. Shimadzu Corporation
    • 8.6.9.1. Company overview
    • 8.6.9.2. Financial performance
    • 8.6.9.3. Product benchmarking
    • 8.6.9.4. Strategic initiatives

관련자료